Vaskulárna medicína 2/2017

Thrombophilia and hepatocellular carcinoma

Thrombophilia is congenital or acquired disorder associated with an increased risk of thrombosis. The most important clinical manifestation of thrombophilia is venous thromboembolism. Predisposing defects are not necessarily the cause or reason for continuous clinical damage, but are to handle certain conditions that are induced by interactions with the outside environment. Incidence of thrombotic complications in patients with malignant disease is higher than in the normal population. There is little data on the concordation of congenital thrombophilia with malignant disease. Thrombophilia may not be undesirable effect of malignancy. It can also be associated with the pathogenesis of a tumor disease because tumor cells benefit from the procoagulant environment with higher growth and metastasis. Hepatocellular carcinoma (HCC) belongs to the sixth most common type cancer and is the third most common cause of death among cancer patients at all. Thrombosis of the portal vein is a common complication HCC. Its patomechanism may be twofold: of either non-malignant origin in chronic liver disease or in connection with malignancy. This high incidence, however, probably correlates with other factors. When identifying risk factors for thrombosis, it would be possible to reduce its incidence by adequate treatment.

Keywords: thrombophilia, hepatocellular carcinoma, portal vein thrombosis